Inhibition of the renin-angiotensin system for lowering coronary artery disease risk

Current Opinion in Pharmacology

Volumn 13, Issue 2, 2013, Pages 274-279

  Sheppard, Richard J ^a   Schiffrin, Ernesto L ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; ALDOSTERONE; ALISKIREN; ANGIOTENSIN; ANGIOTENSIN ANTAGONIST; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; LOSARTAN; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; RENIN; RENIN INHIBITOR; SPIRONOLACTONE; TELMISARTAN; TRANDOLAPRIL; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN;

ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; ENZYME INHIBITION; HEART ARREST; HEART EJECTION FRACTION; HEART INFARCTION; HUMAN; HYPERKALEMIA; HYPOTENSION; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BLOCKING; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; SECONDARY PREVENTION; TREATMENT OUTCOME; VASODILATATION;

EID: 84879385976     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.03.001     Document Type: Review

References (41)

1. S.D. Fihn, J.M. Gardin, J. Abrams, K. Berra, J.C. Blankenship, A.P. Dallas, P.S. Douglas, J.M. Foody, T.C. Gerber, and A.L. Hinderliter 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary Circulation 126 2012 3097 3137
2. Statistics Canada Mortality, Summary List of Causes 2008 2011 (released October 18, 2011)
3. C. Marchesi, P. Paradis, and E.L. Schiffrin Role of the renin-angiotensin system in vascular inflammation Trends Pharmacol Sci 29 2008 367 374
4. J.C. Tardif Angiotensin-converting enzyme inhibitors and atherosclerotic plaque: a key role in the cardiovascular protection of patients with coronary artery disease Eur Heart J 11 2009 E9 E16
5. S. Sitia, L. Tomasoni, F. Atzeni, G. Ambrosio, C. Cordiano, A. Catapano, S. Tramontana, F. Perticone, P. Naccarato, and P. Camici From endothelial dysfunction to atherosclerosis Autoimmun Rev 9 2010 830 834
6. A. Leibowitz, and E.L. Schiffrin Immune mechanisms in hypertension Curr Hypertens Rep 13 2011 465 472
7. A. Nguyen Dinh Cat, and R. Touyz A new look at the renin-angiotensin system - focusing on the vascular system Peptides 32 2011 2141 2150
8. E.L. Schiffrin Vascular remodeling in hypertension: mechanisms and treatment Hypertension 59 2012 367 374
9. J.W. Chen, N.W. Hsu, T.C. Wu, S.J. Lin, and M.S. Chang Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X Am J Cardiol 90 2002 974 982
10. P.C. Keelan, A. Prasad, and G.W. Barsness Improving endothelial function with ACE inhibitors: an important therapeutic target after coronary interventions Curr Interv Cardiol Rep 3 2001 244 250
11. S.R. Willoughby, S. Rajendran, and W.P. Chan Ramipril sensitizes platelets to nitric oxide: implications for therapy in high-risk patients J Am Coll Cardiol 60 2012 887 894
12. B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, B. Roniker, R. Bittman, S. Hurley, J. Kleiman, and M. Gatlin Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321 (Pubitemid 36384098)
13. B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, A. Perez, J. Palensky, and J. Wittes The effect of spironolocatone on morbidity and mortality in patients with severe heart failure N Engl J Med 341 1999 709 717 (Pubitemid 29407370)
14. N. Shah, S. Pringle, and A. Struthers Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure J Renin-Angiotensin-Aldosterone Syst 7 2006 20 30 (Pubitemid 43891241)
15. G. Riccioni, N. Vitulano, A. Zanasi, F. Bellocci, and N. d'Orazio Aliskiren: beyond blood pressure reduction Expert Opin Investig Drugs 19 2010 1265 1274
16. L.M. Ruilope, A. Dukat, M. Böhm, Y. Lacourcière, J. Gong, and M.P. Lefkowitz Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study Lancet 375 2010 1255 1266
17. J. Gu, A. Noe, P. Chandra, S. Al-Fayoumi, M. Ligueros-Saylan, R. Sarangapani, S. Maahs, G. Ksander, D.F. Rigel, and A.Y. Jeng Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) J Clin Pharmacol 50 2010 401 414
18. The Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients N Engl J Med 342 2000 145 153
19. The EUROPA Investigators Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) Lancet 362 2003 782 788
20. The PEACE Trial Investigators Angiotensin-converting-enzyme inhibition in stable coronary artery disease N Engl J Med 351 2004 2058 2068
21. B. Pitt, B. O'Neill, R. Feldman, R. Ferrari, L. Schwartz, H. Mudra, T. Bass, C. Pepine, M. Texter, H. Haber, A. Uprichard, L. Cashin-Hemphill, R.S. Lees QUIET Study Group The Quinapril Ischemic Event Trial (QUIET): evaluation of chronic ace inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function Am J Cardiol 87 2001 1058 1063 (Pubitemid 32710319)
22. F. Enseleit, D. Hurlimann, and T. Luscher Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events Cardiovasc Pharmacol 37 2001 S21 S30
23. M. Al-Mallah, I.M. Tleyjeh, A. Abdel-Latif, and D. Weaver Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function J Am Coll Cardiol 47 2006 1576 1583
24. G.R. Dagenais, J. Pogue, K. Fox, M.L. Simoons, and S. Yusuf Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials Lancet 368 2006 581 588 (Pubitemid 44209181)
25. G. Wiemer, B.A. Scholkens, R.H. Becker, and R. Busse Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin Hypertension 18 1991 558 563
26. I. Kovacs, J. Toth, J. Tarjan, and A. Koller Correlation of flow mediated dilation with inflammatory markers in patients with impaired cardiac function. Beneficial effects of inhibition of ACE Eur J Heart Fail 8 2006 451 459
27. M.A. Pfeffer, J.J. McMurray, E.J. Velazquez, J.L. Rouleau, L. Køber, A.P. Maggioni, S.D. Solomon, K. Swedberg, F. Van de Werf, and W.H. Valsartan Captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 349 2003 1893 1906 (Pubitemid 37409706)
28. The OPTIMAAL Study Group Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial Lancet 360 2002 752 760
29. The Telmisartan Randomised AssessmeNt Study in ACE-iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial Lancet 372 2008 1174 1183
30. The OnTarget Investigators Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 358 2008 1547 1559
31. M. Briet, and E.L. Schiffrin Aldosterone effects on the kidney and cardiovascular system, and clinical value of aldosterone antagonism Nat Rev: Nephrol 6 2010 261 273
32. A.S. Desai, E.F. Lewis, R. Li, S.D. Solomon, S.F. Assmann, R. Boineau, N. Clausell, R. Diaz, J.L. Fleg, and I. Gordeev Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction Am Heart J 162 2011 966 972
33. M. Gheorghiade, M. Albaghdadi, F. Zannad, G.C. Fonarow, M. Böhm, C. Gimpelewicz, J. Botha, S. Moores, E.F. Lewis, H. Rattunde, A. Maggioni ASTRONAUT Investigators and Study Coordinators Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) Eur J Heart Fail 13 2011 100 106
34. H.H. Parving, B.M. Brenner, J.J. McMurray, D. de Zeeuw, S.M. Haffner, S.D. Solomon, N. Chaturvedi, F. Persson, A.S. Desai, M. Nicolaides, A. Richard, Z. Xiang, P. Brunel, M.A. Pfeffer ALTITUDE Investigators Cardiorenal end points in a trial of aliskiren for type 2 diabetes N Engl J Med 367 2012 2204 2213
35. K.E. Chan, T.A. Ikizler, J.L. Gamboa, C. Yu, R.M. Hakim, and N.J. Brown Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients Kidney Int 80 2011 978 985
36. S.D. Solomon, M. Zile, B. Pieske, A. Voors, A. Shah, E. Kraigher-Krainer, V. Shi, T. Bransford, M. Takeuchi, and J. Gong The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial Lancet 380 2012 1387 1395
37. M.J. Sarnak, A.S. Levey, A.C. Schoolwerth, J. Coresh, B. Culleton, L.L. Hamm, P.A. McCullough, B.L. Kasiske, E. Kelepouris, M.J. Klag, P. Parfrey, M. Pfeffer, L. Raij, D.J. Spinosa, P.W. Wilson American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Hypertension 42 2003 1050 1065 (Pubitemid 37413751)
38. H.C. Gerstein, J.F. Mann, and Q. Yi Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals JAMA 286 2001 421 426 (Pubitemid 32681484)
39. B.F. Culleton, M.G. Larson, and P.S. Parfrey Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study Am J Med 109 2000 1 8 (Pubitemid 30608730)
40. Y.W. Chiu, S.G. Adler, M.J. Budoff, J. Takasu, J. Ashai, and R. Mehrotra Coronary artery calcification and mortality in diabetic patients with proteinuria Kidney Int 12 2010 1107 1114
41. B. Mackinnon, C.J. Deighan, W.R. Ferrell, N. Sattar, and J.G. Fox Endothelial function in patients with proteinuric primary glomerulonephritis Nephron Clin Pract 109 2008 c40 c47